Emergency medical technicians (EMT) lift a patient diagnosed with coronavirus disease (COVID-19) into an ambulance while wearing protective clothing during the outbreak of coronavirus disease (COVID-19) in New York City, New York, continues. United States, March 26, 2020.
Stefan Jeremiah | Reuters
The United States reported 67,417 new cases of coronavirus on Tuesday and, according to Johns Hopkins University, set another new record for new cases reported in a single day.
The number of cases in the U.S. continues to grow, averaging 62,210 new cases per day in the past seven days – more than three times the number one month ago, and more than 21% more than the seven-day average, according to CNBC a week's analysis of Hopkins' data.
Texas, California and Florida accounted for 31,847 new cases on Tuesday, nearly half of all new cases reported across the country.
President Donald Trump again attributed the increase in cases to increased testing on Tuesday.
The country processed 760,282 tests on Tuesday, the second highest number of tests performed in a single day. This comes from data compiled by the Covid Tracking Project, an independent volunteer organization created by journalists at The Atlantic. The U.S. processed an average of more than 665,000 tests per day between July 1 and 12. This emerges from a CNBC analysis of the data from the Covid Tracking Project. This corresponds to a daily average of just over 174,000 diagnostic tests, which according to the CNBC analysis are carried out nationwide per day until April.
"Remember, if we didn't test, instead of testing over 40 million people, we would have half the cases if we did half the tests," the president said Tuesday evening. "If we did another one, you'd cut it in half, we'd have half of it again. But the headlines always test."
Trump's medical advisors, including the director of the National Institute for Allergy and Infectious Diseases, Dr. Anthony Fauci said the recent surge in cases is a sign of an increasing outbreak, not of increased testing.
However, in view of the increasing number of new cases, particularly in so-called hot-spot countries in the south and west, the country's test infrastructure has difficulties keeping up. Quest Diagnostics and LabCorp, two of the country's largest diagnostic laboratories, announced earlier this week that increasing demand for tests is slowing their turnaround time. According to Quest, results for patients who are not "Priority 1" are now over seven days. According to public health professionals, the tests are almost unusable to track down cases and isolate exposed people.
Quest said in a statement on Monday that it will not be possible to "shorten our lead times as long as the cases of COVID-19 continue to increase dramatically across much of the United States. This is not just a quest problem. The increase in COVID – 19 cases affect the entire laboratory industry. "
The disease control and prevention centers on Tuesday urged Americans to wear masks to curb the spread of the virus. Director Dr. Robert Redfield said Dr. Howard Bauchner of the Journal of the American Medical Association in an interview on Tuesday that the US could control its outbreak in a month or two if every American were to wear a mask.
"The time is now," said Redfield. "I think if we could get everyone to wear a mask now, we could get this epidemic under control in four, six, eight weeks."
As the health authorities urge the public to take measures to control the virus, the race for a vaccine continues. Moderna said Tuesday that its potential preventive vaccine for Covid-19 in its early human study elicited a "robust" immune response in all 45 patients. This emerges from data published on Tuesday evening in the peer-reviewed New England Journal of Medicine.
All 45 patients produced neutralizing antibodies, which scientists believe are important for building immunity, and provided more promising data that the vaccine could offer some protection against the coronavirus. Moderna's stock in after-hours trading rose more than 16% in the news.
According to a publication released on ClinicalTrials.gov on Tuesday, the company is scheduled to begin the Phase 3 trial on July 27. The study, which will be the most comprehensive test of the potential vaccine to date, will involve 30,000 participants at 87 sites, according to the website.
CNBC's Berkeley Lovelace Jr. and Noah Higgins-Dunn contributed to this report.